[ad_1]

The U.S. Food and Drug Administration (FDA) has approved the weight loss drug Wegovy (semaglutide) to reduce the risk of cardiovascular death, heart disease, and stroke in adults who are overweight or obese. The agency says the shot should be used “in addition to a reduced-calorie diet and increased physical activity.”

“Wegovy is the first weight loss drug approved for use in the prevention of life-threatening cardiovascular events in obese or overweight adults with cardiovascular disease,” said Dr. said John Sharetz, MD. FDA Center for Drug Evaluation and Research Obesity Research Cited in FDA Press Release.

“This patient population is at increased risk of cardiovascular death, heart attack, and stroke. Providing treatment options proven to reduce this cardiovascular risk is a major advance for public health,” he said. added.

Wigoby, which contains the same active ingredient as the type 2 diabetes drug Ozempic, was already approved by the FDA in 2021 for weight loss in overweight or obese adults with at least one other weight-related disease, such as type 2 diabetes and hyperemia. approved by. High blood pressure or high cholesterol.

In a high-profile late-stage clinical trial published in November 2023, Wegovy reduced the risk of heart disease-related death, heart attack, and stroke by 20 percent compared to a placebo in overweight or obese adults with heart disease. Ta.

[ad_2]

Source link